

Insulin-like growth factor-I feedback regulation of growth hormone and luteinizing hormone secretion in the pig: evidence for a pituitary site of action

C. R. Barb[†] and G. J. Hausman

USDA-ARS, Russell Research Center, PO Box 5677, Athens, GA 30604, USA

(Received 29 July 2008; Accepted 24 November 2008; First published online 4 March 2009)

Three experiments (EXP) were conducted to determine the role of insulin-like growth factor-I (IGF-I) in the control of growth hormone (GH) and LH secretion. In EXP I, prepuberal gilts, 65 ± 6 kg body weight and 140 days of age received intracerebroventricular (ICV) injections of saline (n = 4), 25 μq (n = 4) or 75 μq (n = 4) IGF-I and jugular blood samples were collected. In EXP II, anterior pituitary cells in culture collected from 150-day-old prepuberal gilts (n = 6) were challenged with 0.1, 10 or 1000 nM [Ala15]-h growth hormone-releasing hormone-(1-29)NH2 (GHRH), or 0.01, 0.1, 1, 10, 30 nM IGF-I individually or in combinations with 1000 nM GHRH. Secreted GH was measured at 4 and 24 h after treatment. In EXP III, anterior pituitary cells in culture collected from 150-day-old barrows (n = 5) were challenged with 10, 100 or 1000 nM gonadotropin-releasing hormone (GnRH) or 0.01, 0.1, 1, 10, 30 nM IGF-I individually or in combinations with 100 nM GnRH. Secreted LH was measured at 4 h after treatment. In EXP I, serum GH and LH concentrations were unaffected by ICV IGF-I treatment. In EXP II, relative to control all doses of GHRH increased (P < 0.01) GH secretion. Only 1, 10, 30 nM IGF-I enhanced (P < 0.02) basal GH secretion at 4 h, whereas by 24 h all doses except for 30 nM IGF-I suppressed (P < 0.02) basal GH secretion compared to control wells. All doses of IGF-I in combination with 1000 nM GHRH increased (P < 0.04) the GH response to GHRH compared to GHRH alone at 4 h, whereas by 24 h all doses of IGF-I suppressed (P < 0.04) the GH response to GHRH. In EXP III, all doses of IGF-I increased (P < 0.01) basal LH levels while the LH response to GnRH was unaffected by IGF-I (P > 0.1). In conclusion, under these experimental conditions the results suggest that the pituitary is the putative site for IGF-I modulation of GH and LH secretion. Further examination of the role of IGF-I on GH and LH secretion is needed to understand the inhibitory and stimulatory action of IGF-I on GH and LH secretion.

Keywords: GH, IGF-I, LH, pig, pituitary

Introduction

The pattern of growth hormone (GH) secretion, such as GH pulse frequency and amplitude, is of considerable importance for optimal growth. Insulin-like growth factor-I (IGF-I), a 70 amino acid polypeptide, mediates the action of GH on somatic cell growth. The growth axis, like other neuroendocrine systems, functions through the hypothalamic–pituitary and target organ axis interactions. IGF-I has been reported to play a role in the feedback regulation of GH secretion (Muller *et al.*, 1999). To that extent, circulating IGF-I concentrations increased, while serum GH levels decreased with age and/or body weight in the pig (Buonomo *et al.*, 1987; Lee *et al.*, 1993). The decrease in GH secretion is primarily due to a

reduction in the amplitude and frequency of secretory GH pulses (Dubreuil et al., 1987), which is accompanied by an age-related reduction in the GH response to growth hormonereleasing hormone (GHRH) in growing pigs (Dubreuil et al., 1987). Similarly in the rat, an age-related decrease in GH response to GHRH was related to a reduction in pituitary somatotroph sensitivity to GHRH (Niimi et al., 1985). Intracerebroventricular (ICV) administration of IGF-I failed to influence GH secretion in sheep (Fletcher et al., 1995) while intra-pituitary administration suppressed GH secretion. In contrast, ICV administration of a mixture of IGFs suppressed GH secretion (Tannenbaum et al., 1983) and somatomedin-C treatment stimulated somatostatin (SS) release from hypothalamic explants (Berelowitz et al., 1981) in the rat. Thus, the primary site of action of circulating IGF-I concentration on GH secretion is unclear and may, in part, be species dependent.

[†] E-mail: Richard.barb@ars.usda.gov

In addition to its action on somatic cell growth and GH secretion, IGF-I also exerts effects on the reproductive axis. Circulating IGF-I concentrations are elevated at the time of puberty in rodents (Handelsman et al., 1987; Crawford and Handelsman, 1996), primates (Mauras et al., 1996), ruminants (Roberts et al., 1990) and pigs (Prunier and Louveau, 1997). Moreover, IGF-I stimulated gonadotropin-releasing hormone (GnRH) release from hypothalamic explants (Hinev et al., 1991) and LH from rat pituitary cells in culture (Kanematsu et al., 1991). In the pig, IGF-I-stimulated LH release from pituitary cells in vitro was influenced by stage of the estrous cycle of the pituitary donor (Whitley et al., 1995). Hiney et al. (1996) reported that ICV administration of small doses of IGF-I to immature juvenile and peripuberal rats increased LH and this effect was blocked by immunoneutralization of GnRH. Furthermore, Miller and Gore (2001) reported that ICV administration of IGF-I in the rat during puberty and reproductive senescence failed to effect GnRH expression, suggesting that IGF-I may play a role in releasing GnRH rather than stimulating gene expression. The LH response to peripheral administration of IGF-I in castrate male sheep with or without estrogen implants was biphasic with the lower doses stimulating and higher doses inhibiting LH secretion (Adam et al., 1998). Moreover, a directed effect of IGF-I on basal LH secretion from ovine pituitary cells in culture has also been reported (Adam et al., 2000).

Based on the above-cited studies, we hypothesize that circulating IGF-I may act at the level of both the hypothalamus and pituitary to regulate GH and LH secretion. Therefore, three experiments were conducted to test this hypothesis by examining the effect of ICV administration of IGF-I on GH and LH secretion and direct action on the anterior pituitary utilizing pituitary cell culture.

Material and methods

Experiment (EXP I)

Twelve ovary-intact crossbred prepuberal gilts, of $65 \pm 6 \,\mathrm{kg}$ body weight and 140 days of age, were surgically implanted with lateral ICV cannulas using the stereotaxic procedure of Estienne et al. (1990). Animals were individually penned in an environmentally controlled building at a constant temperature of 22°C and artificial 12:12-h light: dark photoperiod. Pigs were fed to appetite daily, at 0800 and 1700 h, a corn-soybean meal ration (14% crude protein) supplemented with vitamins and minerals, according to the National Research Council guidelines (NRC, 1998). At 1 week after the last ICV surgery, and 24h before treatment, all pigs were fitted with an indwelling jugular vein cannula (Barb et al., 1982). On the day of the EXP, pigs were fed at 0700 h and blood sampling started at 0800 h. Blood samples were collected every 15 min from 5 h before to 4 h after ICV injections of 150 μ l 0.9% saline (S; n = 4), 25 μ g (n = 4) or 75 μ g (n = 4) of recombinant IGF-I (GroPrep, Adelaide, Australia) in 150 μ l of S. Serum was harvested and stored at -20° C until assayed for GH and LH by radioimmunoassay (RIA). All procedures were approved by the Richard B. Russell

Agriculture Research Center Committee on Animal Care and Use.

Experiment (EXP II)

Pituitary glands were aseptically removed from 150-day-old prepuberal gilts (n = 6). Ovaries were examined at sacrifice and all gilts were considered prepuberal because their ovaries were devoid of corpora albicantia and corpora lutea. The anterior lobe was dissected from each pituitary gland and cells were enzymatically dispersed and cultured as previously described (Barb et al., 1995). Cells from each pig were cultured separately. Cell viability and number were assessed by counting cells, which excluded trypan blue on a hemocytometer. Cell viability was 96%. Cells were diluted and plated, based on the number of live cells. Cells were plated at 10⁵ cells/ml with a culture medium 60% (vol/vol) Ham's F-I2 nutrient mix, 30% (vol/vol) Dulbecco's modified Eagle's medium (DME); 4500 mg/l glucose (Sigma-Aldrich Corporation, St Louis, MO, USA) and 10% (vol/vol) Fitton-Jackson medium (BGjb; Invitrogen Corporation, Carlsbad, CA, USA) containing 2 mg/ml of BSA, 10 mM HEPES (pH 7.21 100 U/ml of penicillin, 2 mM L-glutamine, 250 ng/ml of amphotericin B (Sigma-Aldrich) and 100 pg/ml of streptomycin (Invitrogen)) to which was added 2% (vol/vol) fetal bovine serum (Sigma-Aldrich), 100 ng/ml of cortisol, 1.0 ng/ml of human insulin, 10 µg/ml of human transferrin (Sigma-Aldrich), 10 pg/ml of glucagon, 100 pg/ml of epidermal growth factor, 200 pg/ml of bovine parathyroid hormone, 400 pg/ml of triiodothyronine (Sigma-Aldrich) and 200 pg/ml of fibroblast growth factor (Collaborative Research, Bedford, MA, USA) in a 24-well cluster plate. Culture medium was changed on day 3 (day of seeding = day 0 of culture) and replaced with serum-free medium as described before (Barb et al., 1995), except for using DME containing 1000 mg of glucose/l (Sigma-Aldrich). On day 4 of culture, the medium was discarded, plates were rinsed twice with serum-free medium and cells were cultured in 1 ml fresh serum-free medium containing one of the following treatments: 0.1, 10 or 1000 nM [Ala15]hGHRH-(1-29)NH₂ (Sigma-Aldrich), 0.01, 0.1, 1, 10, or 30 nM IGF-I individually or in combinations with 1000 nM GHRH. Cells were exposed to treatment for 4 and 24 h, during which time medium was harvested and quantified for GH by RIA.

Experiment (EXP III)

Pituitary glands were aseptically removed from 150-day-old barrows (n=5). Castrate males were utilized to remove the influence of testicular steroids on the pituitary. The anterior lobe was dissected from each pituitary gland and cells were enzymatically dispersed and cultured as previously described above. Cells from each pig were cultured separately and challenged with 10, 100 or 1000 nM GnRH (Sigma-Aldrich, Cat. # L7134) or 0.01, 0.1, 1, 10, 30 nM IGF-I individually or in combinations with 100 nM GnRH. Secreted LH was measured at 4 h after treatment by RIA.

Radioimmunoassays

EXP I and II: Serum and media samples were assayed for GH (Barb *et al.*, 1991) as previously described. Sensitivity of the assays was 0.4 ng/ml and the intra- and inter-assay coefficients of variation were 3.5% and 13%, respectively. Serum and media samples from EXP I and III were assayed for LH (Kesner *et al.*, 1987) as previously described. Sensitivity of the assays was 0.15 ng/ml and intra- and interassay coefficients of variation were 4.5% and 10.2%, respectively.

Statistical analysis

EXP I: To determine the effect of IGF-I on GH and LH secretion, data were subjected to repeated measures using the PROC MIXED ANOVA procedure of Statistical Analysis Systems Institute (SAS; Littell *et al.*, 1996). The statistical model included treatment, pig and time. Effects of treatment were tested using pig within treatment as the error term. Time and time \times treatment were tested using time \times treatment and pig within treatment \times time as the error terms, respectively. Differences between treatment means within a time were determined by least-squares contrasts (SAS, 1999).

EXP II and III: Basal secretion (control; C) was the amount of hormone secreted into the culture medium per 10⁵ cells seeded/well in the absence of treatment or a secretagogue. Cells from each pig were cultured separately. For wells that were treated with GHRH, GnRH or IGF-I alone, data were converted to percentage of basal secretion. Data from wells treated with a combination of GHRH or GnRH with IGF-I data were converted to percentage of the hormone response to GHRH or GnRH alone before averaging to minimize differences between wells. To obtain an estimate of variation between control wells, medium GH and LH concentrations for control wells were converted to a percentage of mean basal GH or LH concentration. This was then used to calculate an SE for basal secretion. Converted data were tested for homogeneity of variance using Hartley's F_{max} test (Gill, 1978). Data were then subjected to a one-way ANOVA and differences between means were determined by least-squares contrast (SAS, 1999).

Results

In EXP I, serum GH and LH concentrations were unaffected by ICV administration of 25 or 75 μ g of IGF-I (Figures 1 and 2). In EXP II, basal (control; C) GH was 48 \pm 2 ng/well at 4h (n=6) and 82 \pm 5 ng/well at 24h (n=6). Relative to C at 4h, 0.1, 10 or 1000 nM GHRH increased (P<0.01) GH secretion by 111%, 125% and 150%, respectively. Relative to C 1, 10, 30 nM IGF-I enhanced (P<0.02) basal GH secretion at 4h whereas by 24h all doses, except for the 30 nM IGF-I, suppressed (P<0.02) GH secretion compared to C wells (Figure 3). All doses of IGF-I in combination with1000 nM GHRH increased (P<0.04) the GH response to GHRH alone at 4h (Figure 4). In contrast, by 24h all doses of IGF-I suppressed (P<0.04) the GH response to GHRH alone (Figure 4). In EXP III, basal




Figure 1 Serum GH concentrations (mean \pm s.e.) in prepuberal gilts receiving ICV injection of saline (n=4), 25 μ g IGF-I (n=4) or 75 μ g IGF-I (n=4) at time 0; arrows indicate time of treatment.




Figure 2 Serum LH concentrations (mean \pm s.e.) in prepuberal gilts receiving ICV injection of saline (n=4), 25 μ g IGF-I (n=4) or 75 μ g IGF-I (n=4) at time 0; arrows indicate time of treatment.

LH secretion was 5.7 \pm 0.7 ng/well (n = 5). Relative to C at 4 h, 10, 100 and 1000 nM GnRH increased (P < 0.0002) LH secretion by 19 \pm 2, 19 \pm 2 and 18 \pm 2-folds, respectively.




Figure 3 Effects of IGF-I on basal GH secretion from anterior pituitary cells at 4 and 24 h in culture. Values are the mean \pm s.e. (n=6 prepuberal gilts/treatment). Control (C) = basal secretion in the absence of treatment. Data expressed as a percentage change from C. Means with different letters differ (P < 0.02) from control.




Figure 4 Effects of IGF-I on GHRH-stimulated GH secretion from anterior pituitary cells at 4 and 24 h in culture. Values are the mean \pm s.e. (n=6) prepuberal gilts/treatment except for the 1 nM dose at 24 h (n=5). Control (C) = GH secretion in the presence of GHRH alone. Data expressed as a percentage change from C. Means with different letters differ (P<0.04).

All doses of IGF-I increased (P< 0.01) basal LH compared to C levels while the LH response to GnRH was unaffected by IGF-I (P> 0.1; Figure 5).

Discussion

In the present study, we report that ICV administration of IGF-I failed to affect GH secretion in the prepuberal gilt. These findings support the observation of Spencer *et al.* (1991 and 1993) and Harel and Tannenbaum (1992a and 1992b), who were unable to demonstrate a central effect of IGF-I on GH secretion and suggested that IGF-I does not play a role in the negative feedback regulation of GH at the level of the brain. To that extent, Fletcher *et al.* (1995)




Figure 5 Effects of IGF-I on basal and GnRH-stimulated LH secretion from anterior pituitary cells at 4 h in culture. Values are the mean \pm s.e. (n=5 barrows). (a) Control (C) = LH secretion in the absence of treatment. Data expressed as a percentage change from C. (b) Control (C) = LH secretion in the presence of GnRH alone. Data expressed as a percentage change from C. Means with different letters differ (P<0.01).

was unable to demonstrate an inhibitory response to IGF-I following either lateral or third ventricle administration or infusion of 5 μg of IGF-I into the third ventricle over a 2 h period. In contrast, in the rat, ICV administration of a mixture of IGFs (Tannenbaum et~al., 1983; Harel and Tannenbaum, 1992b) or somatomedin-C suppressed GH secretion (Abe et~al., 1983). However, the report by Harel and Tannenbaum (1992b) demonstrated that only IGF-I in combination with IGF-II suppressed GH secretion. Moreover, the study by Tannenbaum et~al. (1983) utilized a mixture of IGFs that most likely contained IGF-II and may explain the inhibitory affect on GH secretion. This paradox further strengthens the idea of a pituitary site of action of IGF-I on GH secretion.

This is the first report on the pig to demonstrate that IGF-I exerted a biphasic effect on basal and GHRH-induced GH secretion from anterior pituitary cell in vitro. At 4 h, IGF-I stimulated basal GH secretion in a dose-dependent manner and enhanced the GH response to GHRH. However, by 24 h all but 30 nM dose of IGF-I inhibited basal and all doses inhibited the GHRH-induced GH secretion. Although the 30 nM dose is within the physiologic range (Barb et al., 2001), the failure of IGF-I to affect basal GH secretion at 24 h may, in part, be related to the ligand-mediated down regulation of the receptor, which is dependent on the amount of ligand and time to which the cells are exposed. To that extent, Yamamoto et al. (1993) reported that exposure of rat GC pituitary cells to IGF-I resulted in a timeand concentration-dependent reduction in cell surface IGF-I receptor binding. Thus, constant exposure to 30 nM might have induced a desensitization of the cell to the inhibitory action of IGF-I.

Our findings agree in part with a study by Berelowitz et al. (1981) who reported that somatomedin-C had no

effect on basal or GH-releasing peptide (RP)-induced GH secretion in rat anterior pituitary cells in culture at 4 h but by 24 h somatomedin-C suppressed both basal and GH-RP-stimulated GH secretion. Several reports have confirmed that the inhibitory action of IGF-I on GH secretion under basal and GHRH-stimulated conditions is due to a reduction in GH mRNA in the rat (Yamashita and Melmed, 1986; Morita *et al.*, 1987), teleost (Fruchtman *et al.*, 2000) and human (Yamashita and Melmed, 1986) anterior pituitary cells in culture, suggesting that IGF-I inhibits transcription. This may explain the delayed inhibitory action of IGF-I on GH secretion observed in the present study.

In addition to IGF-I action on somatic cell growth and GH secretion, several reports have demonstrated that IGF-I acts centrally to affect GnRH release and subsequent LH secretion (for a review, see Daftary and Gore, 2005). ICV administration of IGF-I failed to affect LH secretion in the present study, although no negative effect on LH secretion was detected. The lack of a central effect on LH secretion may in part be related to maturational changes in hypothalamic sensitivity to IGF-I as proposed by Daftary and Gore (2003), or possibly the response to IGF-I may vary due to species, gender, and (or) hormonal status and, lastly, IGF-I may serve as a permissive metabolic signal that may be necessary for activation of the reproductive axis but not as a triggering effect on LH secretion (Hiney et al., 1991). This could account for the lack of LH response to ICV administration of IGF-I.

We present evidence that IGF-I stimulated basal LH secretion from anterior pituitary cells in culture from castrate males. This was dose dependent and was similar to that reported in male castrate sheep (Adam et al., 2000), eel (Huang et al., 1998) and mature gilt (Whitley et al., 1995). The LH response to GnRH was unaffected by IGF-I, suggesting that the action of IGF-I on LH release from anterior pituitary cells in vitro was by direct action, independent of GnRH, rather than by enhanced GnRH-induced LH secretion. In contrast, IGF-I stimulated basal and enhanced the LH response to GnRH in rat anterior pituitary cell culture and this response was reduced by 30% with IGF-I antiserum (Soldani et al., 1994 and 1995). The authors suggested that IGF-I may serve as a putative modulator of anterior pituitary LH secretion. This paradox between the current study and those reported by Soldani et al. (1994) may in part be related to species differences.

Conclusions

Under the experimental conditions used in the present study, the results demonstrated a biphasic and time-related effect of IGF-I on basal and GHRH-induced GH release from the anterior pituitary whereas IGF-I only affected basal LH secretion. The role of IGF-I in the feedback regulation of GH and LH secretion at the level of the brain remains to be resolved. Further research is needed to determine the functional role of IGF-I in the regulation of GH and LH secretion in the pig.

Acknowledgments

The authors wish to thank Benny Barrett and Brent Jackson for their technical assistance. The authors wish to thank Dr A. F. Parlow, Harbor-UCLA Medical Center, Torrance, CA, USA for providing the porcine GH antiserum AFP-1021854, porcine GH AFP-10864B and porcine LH AFP-11043B. This research was supported by USDA funds. Mention of a trade name, proprietary product or specific equipment does not constitute a guarantee or warranty by the US Department of Agriculture and does not imply its approval to the exclusion of other products, which may be suitable.

References

Abe H, Molitch ME, Van Wyk JJ and Underwood LE 1983. Human growth hormone and somatomedin-C suppress the spontaneous release of growth hormone in unanesthetized rats. Endocrinology 113, 1319–1324.

Adam CL, Findlay PA and Moore AH 1998. Effects of insulin-like growth factor-1 on luteinizing hormone secretion in sheep. Animal Reproduction Science 50, 45–56

Adam CL, Gadd TS, Findlay PA and Wathes DC 2000. IGF-I stimulation of luteinizing hormone secretion, IGF-binding proteins (IGFBPs) and expression of mRNAs for IGFs, IGF receptors and IGFBPs in the ovine pituitary gland. Journal of Endocrinology 166, 247–254.

Barb CR, Kraeling RR, Rampacek GB, Fonda ES and Kiser TE 1982. Inhibition of ovulation and LH secretion in the gilt after treatment with ACTH or hydrocortisone. Journal of Reproduction and Fertility 64, 85–92.

Barb CR, Estienne MJ, Kraeling RR, Marple DN, Rampacek GB, Rahe CH and Sartin JL 1991. Endocrine changes in sows exposed to elevated ambient temperature during lactation. Domestic Animal Endocrinology 8, 117–127.

Barb CR, Kraeling RR and Rampacek GB 1995. Glucose and free fatty acid modulation of growth hormone and luteinizing hormone secretion by cultured porcine pituitary cells. Journal of Animal Science 73, 1416–1423.

Barb CR, Barrett JB, Kraeling RR and Rampacek GB 2001. Serum leptin concentrations, luteinizing hormone and growth hormone secretion during feed and metabolic fuel restriction in the prepuberal gilt. Domestic Animal Endocrinology 20, 47–63.

Berelowitz M, Szabo M, Frohman LA, Firestone S and Chu L 1981. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science 212, 1279–1281.

Buonomo FC, Lauterio TJ, Caile CA and Campion DR 1987. Determination of insulin-like growth factor-1 (IGF1) and IGF binding protein levels in swine. Domestic Animal Endocrinology 4, 23–31.

Crawford BA and Handelsman DJ 1996. Androgens regulate circulating levels of insulin-like growth factor (IGF)-I and IGF binding protein-3 during puberty in male baboons. Journal of Clinical Endocrinology and Metabolism 81, 65–72.

Daftary SS and Gore AC 2003. Developmental changes in hypothalamic insulinlike growth factor-1: relationship to gonadotropin-releasing hormone neurons. Endocrinology 144, 2034–2045.

Daftary SS and Gore AC 2005. IGF-1 in the brain as a regulator of reproductive neuroendocrine function. Proceedings of the Society for Experimental Biology and Medicine (Maywood) 230, 292–306.

Dubreuil P, Pelletier G, Petitclerc D, Lapierre H, Couture Y, Brazeau P, Gaudreau P and Morisset J 1987. Influence of age and sex on basal secretion of growth hormone (GH) and on GH-induced release by porcine GH-releasing factor pGRF (1-29NH₂) in growing pigs. Domestic Animal Endocrinology 4, 299–307.

Estienne MJ, Kesner JS, Barb CR, Kraeling RR, Rampacek GB and Estienne CE 1990. Gonadotropin and prolactin secretion following intraventricular administration of morphine in gilts. Proceedings of the Society for Experimental Biology and Medicine 193, 92–97.

Fletcher TP, Thomas GB, Dunshea FR, Moore LG and Clarke IJ 1995. IGF feedback effects on growth hormone secretion in ewes: evidence for action at the pituitary but not the hypothalamic level. Journal of Endocrinology 144, 323–331.

Fruchtman S, Jackson L and Borski R 2000. Insulin-like growth factor I disparately regulates prolactin and growth hormone synthesis and secretion: studies using the teleost pituitary model. Endocrinology 141, 2886–2894.

Insulin-like growth factor-I and GH and LH secretion

Gill JL 1978. Completely randomized design and analysis of variance. In Design and analysis of experiments in the animal and medical sciences (ed. JL Gill). Iowa State University Press, Ames.

Handelsman DJ, Spaliviero JA, Scott CD and Baxter RC 1987. Hormonal regulation of the peripubertal surge of insulin-like growth factor-I in the rat. Endocrinology 120, 491–496.

Harel Z and Tannenbaum GS 1992a. Centrally administered insulin-like growth factor II fails to alter pulsatile growth hormone secretion or food intake. Neuroendocrinology 56, 161–168.

Harel Z and Tannenbaum GS 1992b. Synergistic interaction between insulinlike growth factors-I and -II in central regulation of pulsatile growth hormone secretion. Endocrinology 131, 758–764.

Hiney JK, Ojeda SR and Dees WL 1991. Insulin-like growth factor-l: a possible metabolic signal involved in the regulation of female puberty. Neuroendocrinology 54, 420–423.

Hiney JK, Srivastava V, Nyberg CL, Ojeda SR and Dees WL 1996. Insulin-like growth factor I of peripheral origin acts centrally to accelerate the initiation of female puberty. Endocrinology 137, 3717–3728.

Huang YS, Rousseau K, Le Belle N, Vidal B, Burzawa-Ge'rard E, Marchelidon J and Dufour S 1998. Insulin-like growth factor-I stimulates gonadotrophin production from eel pituitary cells: a possible metabolic signal for induction of puberty. Journal of Endocrinology 159, 43–52.

Kanematsu T, Irahara M, Miyake T, Shitsukawa K and Aono T 1991. Effect of insulin-like growth factor I on gonadotropin release from the hypothalamus—pituitary axis *in vitro*. Acta Endocrinologica 125, 227–233.

Kesner JS, Kraeling RR, Rampacek GB and Johnson B 1987. Absence of an estradiol-induced surge of luteinizing hormone in pigs receiving unvarying pulsatile gonadotropin-releasing hormone stimulation. Endocrinology 121, 1862–1869.

Lee CY, Chung CS and Simmen FA 1993. Ontogeny of the porcine insulin-like growth factor system. Molecular and Cellular Endocrinology 93, 71–80.

Littell RC, Milliken GA, Stroup WW and Wolfinger RD 1996. SAS (R) system for mixed models. SAS Institute Inc., Cary, NC, USA.

Mauras N, Rogol AD, Haymond MW and Veldhuis JD 1996. Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Hormone Research 45, 74–80.

Miller BH and Gore AC 2001. Alterations in hypothalamic insulin-like growth factor-I and its associations with gonadotropin releasing hormone neurons during reproductive development and ageing. Journal of Neuroendocrinology 13, 728–736

Morita S, Yamashita S and Melmed S 1987. Insulin-like growth factor I action on rat anterior pituitary cells: effects of intracellular messengers on growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 121, 2000–2006.

Muller EE, Locatelli V and Cocchi D 1999. Neuroendocrine control of growth hormone secretion. Physiological Review 79, 511–607.

Niimi M, Takahara J, Kawanishi K and Irino S 1985. Effects of age on GH responses to growth hormone-releasing factor in rats. Endocrinology Japan 32, 559–562.

National Research Council 1998. Nutrient requirements in swine, 10th edition (National Academy of Sciences). National Academy Press, Washington, DC, USA.

Prunier A and Louveau I 1997. Influence of ovariectomy on metabolic and endocrine parameters during sexual development in the female pig. Journal of Endocrinology 154, 423–429.

Roberts CA, McCutcheon SN, Blair HT, Gluckman PD and Breier BH 1990. Developmental patterns of plasma insulin-like growth factor-1 concentrations in sheep. Domestic Animal Endocrinology 7, 457–463.

Statistical Analysis Systems Institute 1999. SAS user's guide (release 8.0). Statistical Analysis Systems Institute, Inc., Cary, NC, USA.

Soldani R, Cagnacci A, Paoletti AM, Yen SS and Melis GB 1995. Modulation of anterior pituitary luteinizing hormone response to gonadotropin-releasing hormone by insulin-like growth factor I *in vitro*. Fertility and Sterility 64, 634–637.

Soldani R, Cagnacci A and Yen SSC 1994. Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells *in vitro*. European Journal of Endocrinology 131, 641–645.

Spencer GSG, Bass JJ, Hodgkinson SC, Edgley WHR and Moore LG 1991. Effect of intraventricular injection of IGF-I on circulating growth hormone concentrations in the sheep. Domestic Animal Endocrinology 8, 155–160.

Spencer GSG, Berry CJ, Hodgkinson SC and Bass JJ 1993. On the neuroendocrine role of insulin-like growth factors 1 and 2 in the regulation of growth hormone secretion. Molecular and Cellular Neurosciences 4, 538–542.

Tannenbaum GS, Guyda HJ and Posner BI 1983. Insulin-like growth factors: a role in growth hormone negative feedback and body weight regulation via brain. Science 220, 77–79.

Whitley NC, Barb CR, Utley RV, Popwell JM, Kraeling RR and Rampacek GB 1995. Influence of stage of the estrous cycle on insulin-like growth factor-I modulation of luteinizing hormone secretion in the gilt. Biology of Reproduction 53, 1359–1364.

Yamamoto H, Prager D, Yamasaki H and Melmed S 1993. Rat pituitary GC cell insulin-like growth factor-I receptor regulation. Endocrinology 133, 1420–1425.

Yamashita S and Melmed S 1986. Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 118, 176–182.